FY21 consolidated facilities task order d- refurbishment and infrastructure projects focused on facility improvements within the NCI at frederick campus.
Ended Awarded Last action
- Contract number
- 75N91021F00007
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,060,605
Award facts
- Opportunity
-
- NCIOSFM210090 Solicitation number
- Contract value 100% obligated
- $1,060,605.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $19,957 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $86,469 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $323,015 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $174,103 | |
| Original award | $457,061 |
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $1,060,605.00 cost-plus-fixed-fee delivery order contract to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for refurbishment and infrastructure projects focused on facility improvements within the NCI at Frederick campus, with a completion date of March 29, 2024. This award does not have a set-aside designation. Leidos Biomedical Research, as a prime contractor, provides a range of research, development, and production services to federal agencies, with a focus on supporting biomedical research programs at organizations like the NIH. The parent company, Leidos Holdings, Inc., is a global leader in the integration and application of information technology, engineering, and science solutions, and has served as a subcontractor on various federal contracts.
Quick answers
Who was awarded contract 75N91021F00007?
75N91021F00007 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on June 21, 2021.
How much is contract 75N91021F00007 worth?
The government has obligated $1,060,605 on 75N91021F00007.
Is contract 75N91021F00007 an order under another contract?
Yes. 75N91021F00007 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91021F00007 competed?
The extent of competition for 75N91021F00007 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award